Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002721266 | SCV002999510 | uncertain significance | Imerslund-Grasbeck syndrome | 2022-08-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. This variant has not been reported in the literature in individuals affected with CUBN-related conditions. This variant is present in population databases (rs763407147, gnomAD 0.006%). This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 599 of the CUBN protein (p.Gly599Ser). |
Ambry Genetics | RCV002721265 | SCV003647048 | uncertain significance | Inborn genetic diseases | 2022-10-04 | criteria provided, single submitter | clinical testing | The c.1795G>A (p.G599S) alteration is located in exon 15 (coding exon 15) of the CUBN gene. This alteration results from a G to A substitution at nucleotide position 1795, causing the glycine (G) at amino acid position 599 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005034386 | SCV005671788 | uncertain significance | Imerslund-Grasbeck syndrome type 1; Proteinuria, chronic benign | 2024-06-03 | criteria provided, single submitter | clinical testing |